drug · antibody

OMVOH

updated 2mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Interleukin-23

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

OMVOH

trade names

Omvoh

generic

MIRIKIZUMAB-MRKZ

MOA

12.1 Mechanism of Action Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacologic inhibition of IL-23p19 can ameliorate intestinal inflammation. Mirikizumab-mrkz inhibits the release of pro-inflammatory cytokines and chemokines.

indication

1 INDICATIONS AND USAGE OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. OMVOH TM is an interleukin-23 antagonist indicated for the treatment of: moderately to severely active ulcerative colitis in adults ( 1 ) moderately to severely active Crohn's disease in adults ( 1 )

OMVOH

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside